Erschienen in:
01.05.2012
Role of Caudate Lobectomy in Type IIIA and IIIB Hilar Cholangiocarcinoma: A 15-year Experience in a Tertiary Institution
verfasst von:
Alfred Wei-Chieh Kow, Choi Dong Wook, Sun Choon Song, Woo Seok Kim, Min Jung Kim, Hyo Jun Park, Jin Soek Heo, Seong Ho Choi
Erschienen in:
World Journal of Surgery
|
Ausgabe 5/2012
Einloggen, um Zugang zu erhalten
Abstract
Background
Concomitant liver resection for type III hilar cholangiocarcinoma could improve the R0 resection rate and long-term outcome. In the present study, we examine the specific role of caudate lobectomy in liver resection for type IIIA and IIIB hilar cholangiocarcinoma and the prognostic factors for survival in this group of patients.
Methods
We reviewed all patients with type IIIA and IIIB hilar cholangiocarcinoma who underwent liver resection in Samsung Medical Center from January 1995 to July 2010. Patients were divided into those with and without caudate lobectomy (CL). The log rank test and Cox regression analysis were employed to investigate for prognostic factors of survival.
Results
There were 127 patients in this cohort, 57 without CL (44.9%) and 70 with CL (55.1%). The demographics and symptoms of presentation were comparable. The median preoperative bilirubin level was significantly higher in the group undergoing CL (p = 0.017). Patients with CL had a significantly better overall survival (OS) (CL: 64.0 months vs without CL: 34.6 months) (p = 0.010) and disease-free survival (DFS) (CL: 40.5 months vs without CL: 27.0 months) (p = 0.031). Multivariate analysis showed that presence of symptoms (p = 0.025) and positive lymph node (LN) metastasis (p < 0.001) were negative prognostic factors for OS. Furthermore, multivariate analysis for DFS found that caudate lobectomy (p = 0.016) and positive LN metastasis (p = 0.001) were positive and negative prognostic factors, respectively.
Conclusions
Caudate lobectomy contributed to improvement of DFS and OS in type III hilar cholangiocarcinoma. Other prognostic factors include positive LN metastasis and presence of symptoms.